

STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

BACLOFEN

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
BACLOFEN	OZOBAX,		64209	GPI-14	
	BACLOFEN			(75100010002070)	
BACLOFEN	FLEQSUVY,		51885	GPI-14	
	BACLOFEN			(75100010001825)	
BACLOFEN	LYVISPAH		51638	GPI-14	
			51639	(75100010003010),	
			51652	(75100010003020),	
				(75100010003030)	

GUIDELINES FOR USE

- 1. Is the request for Ozobax (baclofen) and the patient meets **ALL** of the following criteria?
 - The patient had a trial of or contraindication to generic baclofen tablets
 - The patient is unable to swallow generic baclofen tablets

If yes, approve for 6 months by GPID or GPI-14 with a quantity limit of #80mL per day. If no, continue to #2.

- 2. Is the request for Flegsuvy (baclofen) and the patient meets ALL of the following criteria?
 - The patient had a trial of or contraindication to generic baclofen tablets
 - The patient is unable to swallow generic baclofen tablets

If yes, approve for 12 months by GPID or GPI-14 with a quantity limit of #16mL per day. If no, continue to #3.

- 3. Is the request for Lyvispah and the patient meets ALL of the following criteria?
 - The patient had a trial of or contraindication to generic baclofen tablets
 - The patient is unable to swallow generic baclofen tablets

If yes, approve for 12 months by GPID or GPI-14 for all strengths with the following quantity limits:

5mg: #9 per day.10mg: #3 per day.20mg: #4 per day.

If no, do not approve.

DENIAL TEXT: See the denial text at the end of the guideline.

CONTINUED ON NEXT PAGE

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 4/26/2023 Page 1 of 2



STANDARD COMMERCIAL DRUG FORMULARY PRIOR AUTHORIZATION GUIDELINES

BACLOFEN

GUIDELINES FOR USE (CONTINUED)

DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **BACLOFEN** (Ozobax, Fleqsuvy, Lyvispah) requires the following rule(s) be met for approval:

- A. You have tried or have a contraindication (harmful for) to generic baclofen tablets
- B. You are unable to swallow generic baclofen tablets

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Ozobax Fleqsuvy, and Lyvispah.

REFERENCES

- Ozobax [Prescribing Information]. Athens, GA: Metacel Pharmaceuticals, LLC; May 2020.
- Flegsuvy [Prescribing Information]. Woburn, MA: Azurity Pharmaceuticals, Inc.: February 2023.
- Lyvispah [Prescribing Information]. Roswell, GA: Saol Therapeutics, Inc.; November 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A Created: 11/19

Commercial Effective: 05/08/23 Client Approval: 04/23 P&T Approval: 07/22

Copyright © 2023 MedImpact Healthcare Systems, Inc. All rights reserved. This document is proprietary to MedImpact. MedImpact maintains the sole and exclusive ownership, right, title, and interest in and to this document.

Revised: 4/26/2023 Page 2 of 2